🔰Why Do Women Quit Iron Tablets? The Real Problem May Be Tolerability—Not Compliance.

Iron-deficiency anaemia is often approached as a simple equation:

Low iron → give iron → haemoglobin rises.

But clinical reality is more complicated.

Many women discontinue oral iron because of nausea, epigastric discomfort, constipation, abdominal symptoms, metallic taste and altered bowel habits. Published evidence reports substantial gastrointestinal intolerance, and studies in women have linked these adverse effects directly with poor adherence.

So perhaps the better question is not:

“Why is the patient non-compliant?”

but:

“Why have we prescribed a regimen the patient cannot comfortably sustain?”

🔹The Applied Unani Lens

Unani medicine offers a different conceptual starting point.

Faqr-ud-Dam is not necessarily interpreted as an isolated deficiency of one mineral. The classical framework considers the quality and formation of Dam, the role of Jigar in humoral production, and the efficiency of Hazm.

From an Applied Unani perspective, this creates a clinically interesting Meda → Jigar → Dam axis:

Meda: Can the patient digest and tolerate the therapy?

Jigar: Is the metabolic environment supportive of effective blood formation?

Dam: Is adequate, healthy blood ultimately being produced?

This does not mean that iron deficiency should be replaced with vague “blood purification” concepts. Confirmed iron-deficiency anaemia still requires appropriate iron replacement and investigation of its cause.

🔹Where Unani Pharmacotherapy Can Contribute

Traditional preparations such as Qurs Kushta Khabs-ul-Hadid, Sharbat Faulad and supportive formulations - Sharbat Unnab deserve systematic investigation—not simply as historical remedies, but through modern questions:

• How much elemental iron do they actually contain?
• What is their chemical and particle profile?
• What is their bioavailability?
• What is their gastrointestinal tolerability?
• How do they affect ferritin, transferrin saturation and haemoglobin?
• Can formulation design improve adherence?

This is where Applied Unani Medicine meets modern pharmacology.

Interestingly, modern iron research itself is moving beyond the old “more iron = better treatment” approach. Hepcidin regulates intestinal iron absorption, and repeated or divided dosing can reduce subsequent absorption. Lower-dose and alternate-day strategies may improve tolerability in selected patients.

Therefore, the future may not be Unani versus modern iron.

It may be:

Better iron + better formulation + better gastrointestinal tolerance + better patient adherence.

That is the real opportunity for Applied Unani Pharmacotherapy:

Not merely replacing iron—but designing a clinically sustainable pathway for iron delivery and blood restoration.

The next step should be rigorous comparative research between standard oral iron and validated Unani iron formulations, with haemoglobin, ferritin, TSAT, GI adverse effects, adherence and safety as measurable endpoints.

From traditional formulation → standardized pharmacology → controlled clinical evidence.

That is how Unani medicine can move from traditional use to evidence-generating applied therapeutics. 

Comments

Popular posts from this blog

🔰Liver-Centric Cholesterol Regulation

🔰Why Does Human Temperament Change Throughout Life? A Unani Perspective on the Four Stages of Sinn

🔰How Genomics Can Help a Unani Physician in Precise Mizaj Evaluation: A New Frontier of Precision Unani Medicine